Compare BOX & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOX | INDV |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.7B |
| IPO Year | 2014 | 2014 |
| Metric | BOX | INDV |
|---|---|---|
| Price | $23.95 | $32.56 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $35.57 | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 1.8M |
| Earning Date | 05-26-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | 0.58 | ★ 1.64 |
| Revenue | $506,142,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | $9.41 | N/A |
| Revenue Next Year | $8.15 | N/A |
| P/E Ratio | $40.92 | ★ $19.95 |
| Revenue Growth | ★ 26.98 | 4.29 |
| 52 Week Low | $21.34 | $8.69 |
| 52 Week High | $38.80 | $38.00 |
| Indicator | BOX | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 52.36 | 54.69 |
| Support Level | $23.29 | $31.70 |
| Resistance Level | $24.55 | $35.75 |
| Average True Range (ATR) | 0.88 | 1.25 |
| MACD | 0.12 | 0.30 |
| Stochastic Oscillator | 80.84 | 74.01 |
Box is a cloud-based content management platform that provides storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file, sync, and share provider. Over time, it built out and acquired workflow and security tools to evolve the pure-play FSS business into a content management business. Most recently, Box has been pursuing an AI-powered, intelligent content management strategy that can allow for metadata extraction and workflow automation.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).